Although immune checkpoint blocking monoclonal antibodies such as PD-1, PD-L1 and CTLA-4 have shown significant prospects in some cancers, the treatment response of ovarian cancer still remains unsatisfied [5, 6]. This evidence concerns the gene PDCD1 and ovarian cancer.